May 30, 2012

McCarthy Statement on the Food and Drug Administration Reform Act

Washington D.C. – House Majority Whip Kevin McCarthy (CA-22) released the following statement on House passage of the Food and Drug Administration Reform Act (H.R. 5651):

“America leads the world in medical device and biopharmaceutical research and development because our economy promotes and rewards innovation and competition. We benefit tremendously from being home to these industries not only because patients are the first to benefit from their breakthrough scientific and medical discoveries, but also because of the millions of good-paying jobs they support – including 270,000 jobs in my home state of California alone.

“Washington’s overregulation is forcing many of these companies to ship American innovation and jobs overseas to friendlier business climates. Foreign countries have worked to exploit our broken regulatory process by reforming and streamlining their own in order to entice businesses to leave our shores. As a result we’ve fallen behind our global competitors. For instance it can take four years longer for bureaucrats to approve certain new technologies in the United States than in Europe because of a cumbersome and unpredictable Food and Drug Administration (FDA) approval process. The Food and Drug Administration Reform Act, reauthorizes the FDA user fee programs to ensure continuation of FDA programs coupled with robust policy reforms to facilitate a more timely, predictable and transparent review and approval process to ensure patient access to quality life-saving drugs and medical devices and continued innovation, investment and job creation here in the United States. I applaud the overwhelming bipartisan passage of this bill which is essential to keeping American innovation and jobs on our shores as well as ensuring we remain the world leader in this vital industry.”